nCounter® Fibrosis Panel
Helping Your Research
The cellular and molecular basis for fibrotic disease is still poorly understood, and the lack of biomarkers for progression and therapeutic response have hampered efforts to develop treatments. The nCounter Fibrosis Panel helps uncover the mechanisms of disease pathogenesis, identify biomarkers of progression, and develop signatures for therapeutic response. This gene expression panel combines hundreds of genes involved in the initial tissue damage response, chronic inflammation, proliferation of pro-fibrotic cells, and tissue modification that leads to fibrotic disease of the lungs, heart, liver, kidney, and skin.
How it Works
Profile 770 genes across 51 annotated pathways in human or mouse.
Study pathogenesis and identify biomarkers for fibrotic diseases of the lungs, heart, liver, kidney, and skin
Elucidate the mechanism of action behind the four stages of fibrosis: initiation, inflammation, proliferation, and modification
Understand the signaling cascade from cell stress to inflammation
Quantify the relative abundance of 14 different immune cell types
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler
Breast cancer is a heterogenous disease with variability in tumor cells and in the surrounding tumor microenvironment (TME). Understanding the molecular diversity in breast cancer is critical for improving prediction of therapeutic response and prognostication.
Spatially organized multicellular immune hubs in human colorectal cancer.
Immune responses to cancer are highly variable, with mismatch repair-deficient (MMRd) tumors exhibiting more anti-tumor immunity than mismatch repair-proficient (MMRp) tumors. To understand the rules governing these varied responses, we transcriptionally profiled 371,223 cells from colorectal tumors and adjacent normal tissues of 28 MMRp and 34 MMRd individuals.
Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.
Histiocytic sarcoma (HS) is a rare and aggressive tumor in humans with no universally agreed standard of care therapy. Spontaneous canine HS exhibits increased prevalence in specific breeds, shares key genetic and biologic similarities with the human disease, and occurs in an immunocompetent setting.